During early drug development and preclinical development, researchers use in vitro cultured lymphocytes to induce cytokine ...

Researchers at the University of California Davis Comprehensive Cancer Center have uncovered an evolutionary change that may ...

Host mice deficient in IFNγ receptors showed uncontrolled leptomeningeal tumor growth, yet subcutaneous or orthotopic tumors remained unchanged. T cells emerged as the primary source of IFNγ ...

Tumor cells often secrete lncRNAs into the surrounding stroma, where they can bind to receptors on stromal cells and alter their behavior, thus reinforcing tumor cell growth and survival.

Here’s how it treats tenosynovial giant cell tumor (TGCT). Skip ... These kinases, called colony-stimulating factor 1 receptors ... A CR is when all of the tumor has disappeared and a PR is when ...

T cells are a natural part of the immune system designed to fight infections and cancer, but in conditions like blood cancer, they may not be able to eliminate malignant cells, according to Dr.

Engineered cell therapies rely on synthetic receptors to transduce external signals into intracellular responses. The precise ...

The breakthrough, appearing in Nature on Nov. 14, revolves around engineered receptors on the surface of cells that can sense molecules in the surrounding environment and, in response, change the ...

Traits of noncancerous cells in diffuse large B-cell lymphoma (DLBCL) tumors appear to offer insight into which patients will benefit the most from chimeric antigen receptor (CAR) T-cell therapy ...

The FDA approved Adaptimmune Therapeutics’ Tecelra as a treatment for advanced cases of synovial sarcoma. It’s the first engineered cell therapy approved for treating a solid tumor.

That led them to develop new receptors, now called SNIPRs (synthetic intramembrane proteolysis receptors), which can bind to soluble, or free-floating, molecules in the environment around a cell.